Consegna Pharma

Consegna Pharma is a biotechnology company specializing in the development of long-acting injectable (LAI) formulations through its proprietary Lingua computational platform. The Lingua technology integrates advanced mathematical modeling and artificial intelligence with polymer science to predict and optimize drug release profiles, significantly accelerating the formulation development process. By transforming existing medications into long-acting versions, the company aims to improve patient adherence and clinical outcomes in chronic conditions. Consegna's internal pipeline primarily focuses on central nervous system disorders, including opioid use disorder and schizophrenia, as well as applications in pain management and ophthalmology. The company operates as a technology-driven developer, leveraging its platform to reduce the time and cost associated with traditional trial-and-error drug delivery research.